CN109207523A - 基于ucp1基因的人类肥胖症斑马鱼模型的建立与应用 - Google Patents
基于ucp1基因的人类肥胖症斑马鱼模型的建立与应用 Download PDFInfo
- Publication number
- CN109207523A CN109207523A CN201710545563.2A CN201710545563A CN109207523A CN 109207523 A CN109207523 A CN 109207523A CN 201710545563 A CN201710545563 A CN 201710545563A CN 109207523 A CN109207523 A CN 109207523A
- Authority
- CN
- China
- Prior art keywords
- ucp1
- zebra fish
- gene
- human obesity
- screening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000252212 Danio rerio Species 0.000 title claims abstract description 75
- 208000008589 Obesity Diseases 0.000 title claims abstract description 37
- 235000020824 obesity Nutrition 0.000 title claims abstract description 36
- 101150022052 UCP1 gene Proteins 0.000 title claims abstract description 19
- 101100403108 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mud1 gene Proteins 0.000 claims abstract description 63
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 42
- 108091033409 CRISPR Proteins 0.000 claims abstract description 32
- 230000035772 mutation Effects 0.000 claims abstract description 27
- 108091027544 Subgenomic mRNA Proteins 0.000 claims abstract description 21
- 238000012216 screening Methods 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000009825 accumulation Methods 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 238000003209 gene knockout Methods 0.000 claims abstract description 5
- 108700028369 Alleles Proteins 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 230000014509 gene expression Effects 0.000 claims description 5
- 241000251468 Actinopterygii Species 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 230000004720 fertilization Effects 0.000 claims description 2
- 108700008625 Reporter Genes Proteins 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 238000012239 gene modification Methods 0.000 claims 1
- 239000002547 new drug Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 108700024526 zebrafish sox32 Proteins 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 abstract description 15
- 238000004458 analytical method Methods 0.000 abstract description 8
- 238000013461 design Methods 0.000 abstract description 7
- 238000012790 confirmation Methods 0.000 abstract description 5
- 238000005520 cutting process Methods 0.000 abstract description 3
- 101150076348 FTO gene Proteins 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 210000001161 mammalian embryo Anatomy 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 10
- 210000003486 adipose tissue brown Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 9
- 235000013601 eggs Nutrition 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 6
- 230000013020 embryo development Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000005782 double-strand break Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 231100000221 frame shift mutation induction Toxicity 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 101100008047 Caenorhabditis elegans cut-3 gene Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000448255 Congiopodus peruvianus Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000007683 Pediatric Obesity Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical class [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000003109 clavicle Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000027721 electron transport chain Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 101150009602 mesh gene Proteins 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000006780 non-homologous end joining Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 235000011091 sodium acetates Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 231100001265 toxicological assessment Toxicity 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/40—Fish
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Environmental Sciences (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Mycology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明涉及基于UCP1基因的人类肥胖症斑马鱼模型的建立与应用,具体步骤包括针对斑马鱼ucp1基因编码关键功能结构域的外显子设计CRISPR序列,筛选确认可有效引导Cas9切割目标基因的活性sgRNA,然后运用有活性的sgRNA,制备ucp1基因敲除的初建者,待初建者生长至性成熟,令其自由交配,产生F1代;通过对F1个体的基因型鉴定,筛选fto基因敲除的斑马鱼突变体;通过对ucp1基因纯合突变的分析,确立ucp1的功能缺失有益于斑马鱼仔鱼的脂肪累积的减少,建立基于ucp1基因的人类肥胖症的斑马鱼模型,进而将ucp1作为标识基因应用于筛选与建立治疗人类肥胖症的新药物与新方法。
Description
技术领域
本发明属于生物技术领域,涉及筛选确定可对斑马鱼ucp1基因进行基因组编辑的sgRNA序列、制备斑马鱼ucp1基因靶向突变的优选方案,以及利用斑马鱼ucp1作为标志性基因筛选治疗人类肥胖症药物的斑马鱼模型的应用。
技术背景
肥胖是体内多余的脂肪堆积超过一定程度对人类健康造成困扰的能量代谢失衡的慢性疾病。人们通常用BMI(body mass index,体重指数)来判断个体是否肥胖。因体脂增加使体重超过标准体重20%或体重指数【BMI=体重(Kg)/(身高)2(m2)】大于24者称为肥胖症。肥胖会增加其它疾病的患病几率,尤其是心脏病、II型糖尿病、阻塞性睡眠呼吸窘迫、癌症和骨关节炎等疾病。近几十年来,肥胖症患者在全球范围内以惊人的速度增加。尤其是儿童、青少年肥胖增长日益迅猛(1,2)。在2014年约有600万成年人(13%) 和4200万5岁以下儿童患有肥胖症。肥胖被认为是21世纪最为严重的影响健康的疾病。
肥胖的病因主要分为外因和内因,外因以饮食过多,活动过少为主,热量摄入多余热量消耗,使脂肪合成增加(3,4)。而内因是要是由于遗传易感性引起的。类似于其它许多疾病,肥胖是遗传因素和环境因素之间相互作用的结果。人类的单纯性肥胖的发病有一定的遗传背景。许多基因存在的多态性控制着食欲和代谢从而在充足能量存在时更容易使体重增加从而易患肥胖症。在对家庭以及双胞胎的研究中表明, 40-70%的普通肥胖症患者属于遗传性肥胖(5,6)。
已有的研究数据表明,UCP1(热解偶联蛋白1)基因与肥胖症密切相关,UCP1存在于褐色脂肪组织内 (BAT)的线粒体膜上,棕色脂肪组织(BAT)线粒体与其他组织的对应物不同,因为ATP生产不是其主要的生理作用,BAT线粒体内有UCP1蛋白质,UCP1使电子传递链短路,使线粒体膜电位转变为热,使 BAT成为能够改变哺乳动物能量消耗和燃料代谢而不增加身体活动的组织(7,8)。之前的研究认为在人类中,BAT在妊娠期间的胎儿体内存在,胎儿发育期间UCP1的量增加,在出生前达到峰值,而在出生后前9个月开始下降(9,10)。直到2009年才发现BAT广泛存在于成年人的锁骨、颈、脊椎旁和肾上腺体中 (11)。BAT是哺乳动物不发热的主要部位,啮齿类动物研究表明,BAT产热活动可以保护免受肥胖。Ucp1 活性高可以有效避免肥胖,而Ucp1功能受损的小鼠中产热机制受损从而会导致肥胖(12)。2015年研究发现,Cnot7-/-和Tob-/-的小鼠中脂肪含量特别少,即使喂食高脂肪食物依然能够保持苗条,在这些小鼠的组织中发现,Ucp1的表达是增强的,Ucp1可通过把脂肪细胞内的脂肪转化成热能来减少脂肪囤积(13)。这些数据表明FTO基因的突变跟肥胖症密切相关。
在分子生物学水平上,小鼠、非洲爪蛙、斑马鱼、果蝇、和线虫等模式动物内的是生物学事件与人享有相同的分子机制。因此,利用模式动物可以制作人类疾病的有效在体模型。在所有模式动物中,斑马鱼是连接无脊椎动物和哺乳动物模型之间的桥梁,人类基因中的87%在其中能找到同源基因。目前,全球有超过1000家实验室选择以斑马鱼作为模式动物开展从基础生物学、环境毒理评价到药物研发等不同研究领域的研究,国内有超过100家实验室以斑马鱼为主要研究对象。斑马鱼饲养简单,饲养环境控制在一定产卵量多,每次一对鱼每周可产卵200-300枚,胚胎发育透明,且发育周期较短,是进行胚胎发育机理,基因组研究以及疾病机理研究的好材料。
就与人类肥胖症密切相关的易感基因UCP1而言,人UCP1基因位于第4号染色体,UCP1蛋白由307 个氨基酸组成;而在斑马鱼中,跟人UCP1同源基因ucp1位于斑马鱼1号染色体,蛋白由309个氨基酸组成。生物信息学分析发现,ucp1基因和人UCP1基因为直系同源基因。在其表达产物蛋白质的氨基酸组成上,发现UCP1与Ucp1的相同性(identity)高,三个功能域(分别是Mito_carr)相同性更高,进一步支持UCP1基因在人和斑马鱼基因组中高度保守。
基于以上原因,我们以斑马鱼为模型,采用基因组编辑技术,靶向突变ucp1基因。对突变体的分析发现,ucp1的纯合突变导致脂肪细胞在斑马鱼体内的堆积显著减少。结果表明ucp1是一个与肥胖相关基因,可以用作筛选治疗肥胖症的标识基因。
参考文献:
1.Weiss R,Dziura J,Burgert TS,Tamborlane WV,Taksali SE,et al.,Obesityand the metabolic syndrome in children and adolescents.N Engl J Med.2004,350(23)
2.Fleisch AF,Agarwal N,Roberts MD,Han JC,Theim KR,et al.,Influence ofserum leptin on weight and body fat growth in children at high risk for adultobesity.J Clin Endocrinol Metab.2007,92(3):948-954.
3.Abelson P,Kennedy D.The obesity epidemic.Science 2004;304:1413.
4.Keith SW,Redden DT,Katzmarzyk PT,Boggiano MM,Hanlon EC,et al.,Putative contributors to the secular increase in obesity:exploring the roadsless traveled.Iht J Obes 2006;30:1585-1594.
5.Maes HH,Neale MC,Eaves LJ.Genetic and environmental factors inrelative body weight and human obesity. Behav Genet 1997;27:325-351.
6.Clement K,Sorensen TIA.Obesity:Genonics andPostgenonic.InformaHealthcare:New York,2008.
7.Ricquier,D.(2011).Uncoupling protein 1of brown adipocytes,the onlyuncou-pler:a historical perspective. Front.Endocrinol.(Lausanne)2,85.
8.Rousset,S.,Alves-Guerra,M.C.,Mozo,J.,Miroux,B.,Cassard-Doulcier,A.M.,Bouillaud,F.,and Ricquier,D. (2004).The biology of mitochondrial un-coupling proteins.Diabetes 53(Suppl 1),S130-S135.
9.Nedergaard,J.,Bengtsson,T.,and Cannon,B.(2007).Unexpected evidencefor active brown adipose tissue in adulthumans.Am.J.Physiol.Endocrinol.Metab.293,E444-E452.doi:10.1152/ajpendo.00691.2006
10.Lean,M.E.,James,W.P.,Jennings,G.,and Trayhurn,P.(1986).Brownadipose tissue uncoupling protein content in human infants,children andadults.Clin.Sci.71,291-297.
11.Feldmann,H.M.,Golozoubova,V.,Cannon,B.,and Nedergaard,J.(2009).UCP1ablation induces obesity and abolishes diet-induced thermogenesis inmiceexempt from thermal stress by living at thermoneutrality.Cell Metab. 9,203-209.
12.Akinori,T.Shungo,Adachi.Masahiro,M.Miho,T.Tohru,N.Toru,S.andTadashi,Y.(2015) Post-transcriptional Stabilization of Ucp1mRNA Protects Micefrom Diet-Induced Obesity.Cell Report 13,2756-2767.
发明内容
为建立人类肥胖症的斑马鱼模型,我们利用CRISPR/Cas9基因组编辑技术靶向敲除ucp1基因,确认ucp1 基因对以脂肪堆积为特征的肥胖症发生的影响。CRISPR/Cas9技术是否能成功编辑ucp1基因,实现斑马鱼 ucp1的基因敲除,关键在于是否能筛选到可以有效引导Cas9识别目标基因序列(CRISPR序列)的sgRNA。当sgRNA能够有效引导Cas9靶向识别目标基因,其中的Cas9就可以将CRISPR序列之PAM前的3至4核苷酸间的3′-5′磷酸二酯键切断,从而形成基因组DNA的双链断裂(DSB)。一旦DSB形成,胚胎细胞将启动非同源末端连接修复或微同源末端连接修复机制,修复基因组的DSB,导致在DSB处引入***缺失(Indel)突变。通过在F1代筛选携带具移码突变基因的突变体,就可以获得ucp1基因敲除的斑马鱼突变体,从而有望了解ucp1在肥胖症发生中的作用。为实现这一目标,我们根据Ucp1的功能域的分析,将CRIPSR序列设计在第一个功能域所对应的第4外显子上。我们共设计了4个CRISPR序列(表一)。依据上述CRISPR 序列,我们制备了相应的sgRNA(sgRNA1至sgRNA4)。运用显微注射技术,将获得的4个sgRNA与体外转录获得的Cas9mRNA共同注射到斑马鱼受精卵中,对所述sgRNA进行活性验证。依据活性验证的结果,本发明首先提供了两个可以有效引导Cas9识别目标CRISPR序列的sgRNA1和sgRNA3。
将sgRNA1和sgRNA3与Cas9蛋白共注射入斑马鱼受精卵(F0),待注射胚胎发育至性成熟时,令其自由交配,获得F1个体。通过剪取尾鳍,对F1个体进行基因型鉴定。依据基因型鉴定的结果,本发明又提供了携带ucp1基因敲除突变的斑马鱼突变体的制备方案。
待F1杂合子生长至性成熟时,将F1自交,获得F2代胚胎。待胚胎发育至受精后4天(4dpf),以油红对胚胎进行染色分析,依据分析结果,我们发现:当斑马鱼ucp1功能缺失时,胚胎的脂肪堆积量显著下降。由此,本发明再提供了基于斑马鱼ucp1基因的人类肥胖症模型,斑马鱼ucp1可作为筛选治疗肥胖症药物的标志基因,即能够使ucp1表达下降的任何物质将具备抑制肥胖症的作用。
附图说明
图1斑马鱼Ucp1蛋白质的保守结构功能域分析。斑马鱼Ucp1包含三个保守功能域,均为Mito_carr superfamily。
图2可有效引导Cas9靶向切割ucp1基因的sgRNA活性验证分析。利用Vector NTI软件对重组子测序序列进行比对分析(共10个重组子),表明sgRNA1、sgRNA3有活性,且活性率均不低于11%。
图3斑马鱼F1代突变体3号携带的ucp1突变等位基因部分序列的测序峰图。
图4斑马鱼F1代突变体3号携带的ucp1突变等位基因预测编码的截短蛋白结构示意图。WT:野生型Ucp1 蛋白质结构示意图;MUT1:其中一个ucp1突变等位基因突变后预测形成的蛋白质结构示意图,MUT2:第二个ucp1突变等位基因突变后预测形成的蛋白质结构示意图。
图5斑马鱼F1代突变体15号携带的ucp1突变等位基因部分序列的测序峰图。
图6斑马鱼F1代突变体15号携带的ucp1突变等位基因预测编码的截短蛋白结构示意图。WT:野生型 Ucp1蛋白质结构示意图;MUT2:第二个ucp1突变等位基因突变后预测形成的蛋白质结构示意图。
图7携带ucp1纯合突变的斑马鱼突变体仔鱼内脂质储存量减少。油红O对发育到4天的斑马鱼仔鱼进行染色,发现与野生型斑马鱼相比较,ucp1突变体斑马鱼仔鱼体内脂肪含量明显减少。
具体实施方式
实施例中的实验方法,如无特殊说明,均为常规方法。
实施例1活性sgRNA的筛选
(一)靶向突变斑马鱼ucp1基因的CRISPR的设计
1、基因信息分析
1.1斑马鱼ucp1基因的CDS序列
ATGGTGGGTCTGAAGCCGTCAGATGTTCCTCCTCCTCTGACTGTGAAGGTGTTGAGTGCAGGAACGGCCGCCTGCATCGCTGACCTCGTCACCTTCCCGCTGGACACGGCCAAAGTCCGCCTGCAGATCCAGGGGGAGAAAGCGGTGACAGGAGCCGCTAAAGGCATCCGCTACAAAGGTGTTTTCGGGACCATCAGCACCATGATGAGGACGGAGGGTCCGCGCTCGCTCTACAACGGCCTGGTCGCCGGCCTACAGAGACAGATGGCCTTCGCCTCCATCCGCATTGGCCTCTACGACAACGTCAAGAGCTTCTACACGCGTGGAAAAGACAACCCTAATGTGGCGGTGCGAATCCTGGCGGGCTGTACTACCGGAGCGATGGCCGTGTCCATGGCTCAGCCCACAGACGTGGTAAAGGTGCGTTTCCAGGCCCAAATGAACCTCCAGGGTGTGGGCAGACGATACAACGGCACCATGCAGGCCTACAGGCAGATCTTCCAGCTTGAGGGACTCCGTGGTCTCTGGAAAGGAACTCTGCCGAACATCACGAGGAACGCTCTGGTCAACTGCACAGAACTGGTGTCTTACGATCTGATCAAAGAGGCTATCCTTAAACACAGACTCCTGTCAGACAATCTCCCGTGTCACTTTGTGTCTGCGTTCGGCGCGGGCTTCATCACGACGGTGATCGCGTCTCCTGTGGATGTGGTAAAAACACGGTACATGAACTCTCCACCGGGACAGTACAGCAGCTCCACCAACTGCGCCTGGACCATGCTCACTAAAGAGGGACCCACAGCTTTCTACAAAGGTTTTGTCCCGTCATTCCTGCGGCTGGGCTCCTGGAACGTGGTGATGTTCGTGTCGTTTGAGCAGCTCAAACGGGCCATGATGGTGTCCAGAAACAGAATCGAAGCCGCTGCGTAG
1.2斑马鱼Ucp1蛋白质序列
1.3蛋白质的保守结构功能域
见图1。
2、CRISPR的设计
2.1斑马鱼ucp1基因的外显子3序列
黄色字体为设计的CRISPR。下划线的序列为PAM序列NGG(RC:CCN)。
表一、靶向突变斑马鱼ucp1基因之CRISPR序列
(二)靶向突变斑马鱼ucp1基因的sgRNA活性的鉴定
1、目标基因的基因型鉴定
1.1待扩增的目标基因组序列
黄色高亮标记为设计的CRISPR,带下划线的为PAM序列NGG(RC:CCN),绿色高亮标记为引物序列。
1.2PCR扩增的引物设计
序列名称 | 序列 | 用途 |
F-ucp1-1 | cagtgcacacacattatgtcaa | PCR正向引物 |
R-ucp1-1 | gcatatttcagcatccattgc | PCR反向引物 |
2、sgRNA的体外合成
2.1sgRNA模板的制备(PCR法)
2.1.1PCR引物
正向引物序列如下:
注:灰色高亮部分为T7启动子部分,下划线部分为ucp1特异的CRISPR序列,小写字母为部分与sgRNA 骨架模板互补的序列。
反向引物(为通用引物)R-Common:AAAAAAAGCACCGACTCGGTGCCAC
2.1.2预计获得的sgRNA体外转录模板序列
注:红色高亮部分为T7启动子部分,下划线部分为ucp1特异的的CRISPR序列,小写字母为sgRNA骨架模板序列。
2.2sgRNA的体外转录
2.2.1体外转录过程
将上述纯化后的模板用T7RNA聚合酶进行体外转录。使用RNA体外转录试剂盒(MAXIscript SP6/T7, Ambion,USA),按试剂盒说明书要求依次加入10×TranscriptionBuffer 2μl、10mM ATP 1μl、10mM CTP 1μl、 10mM GTP 1μl、10mM UTP 1μl、T7RNApolymerase mix 2μl、模板DNA 12μl,轻弹混匀离心后,37℃水浴1h。
加入DNase I(Ambion,USA)1μl,37℃水浴15min,以去除模板。
之后加入30μl DEPC水扩大体积至50μl,同时加入5μl无核酸酶3M醋酸钠(pH5.2)和3倍体积的无水乙醇(国产分析纯),-80℃沉淀过夜。4℃12,000g离心20min,去除上清后,沉淀在通风橱晾干,然后以 15μl无核酸酶超纯水重悬后储存于-80℃冰箱备用。
2.2.2sgRNA序列
UCP1-sgRNA1:
GGAUUCGCACCGCCACAUUAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU
UCP1-sgRNA2:
GGGCUGUACUACCGGAGCGAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU
UCP1-sgRNA3:
GACCACGGAGUCCCUCAAGCGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU
UCP1-sgRNA4:
GGUGUGGGCAGACGAUACAAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU
3、Cas9蛋白
将从商业公司(金丝瑞)购买的Cas9蛋白用DEPC水稀释为400ng/μl,分装后置于-20℃冰箱中保存。
4、斑马鱼受精卵的显微注射
按常规方法收取斑马鱼受精卵。将上述sgRNA1、sgRNA2、sgRNA3、sgRNA4(终浓度为50ng/μl)和 Cas9蛋白(终浓度为200ng/μl)混合后,显微注入斑马鱼受精卵,注射量为1nl每胚胎。
5、目标基因编辑子(Edits)的重组确认
5.1目标基因组片段模板的制备
待注射胚胎发育至24hpf时,各取5枚胚胎,使用南京尧顺禹公司生产的《斑马鱼基因型鉴定试剂盒》制备基因组DNA模板,具体反应条件为:65℃30min,95℃5min,16℃1min,4℃
5.2PCR扩增反应体系(20μl)
2×Mastermix(Transgene)10μl、7μl的超纯水、1μl的正反向(F1-ucp1-1和R1-ucp1-1)引物(5μM)、和1μl的由5.1制备好的基因组DNA模板。
5.3PCR反应条件
95℃3min,30×(95℃30s,56℃30s,72℃1min),72℃10min,4℃。
5.4目标基因PCR扩增产物的重组
将F1-ucp1和R1-ucp1的PCR扩增产物重组入pGEM-T Easy载体(5μl总体积的反应),反应组成为:
1.5μl PCR扩增产物(取自5.5.2)
2.5μl 2×Ligation Buffer
0.5μl T4DNA连接酶
0.5μl pGEM-T Easy载体(Promega)
反应时间为:室温孵育60min
5.5重组子转化
将上述5μl连接产物用100μl大肠杆菌DH5α感受态细胞(pfu≥108)进行转化。然后涂布于含氨苄(50 μg/ml)的LB板,37℃下倒置培养过夜。
5.6目标基因组DNA编辑子(Edits)的重组确认
依据条带大小,选取克隆直接送测序,测序引物为T7。送测10个克隆,测序结果反馈10个,具体序 列比对见图2。结果显示sgRNA1和sgRNA3有活性,且活性率均不低于11%。
图2目标基因组DNA编辑子(Edits)序列比对图sgRNA1、sgRNA3有活性,且活性率均不低于11%。
6、结论:
综合以上实验结果,可以确认所述的sgRNA1和sgRNA3可有效引导Cas9靶向切割目标基因。
实施例2斑马鱼ucp1基因敲除突变体制作方案
(一)初建者的制备
按实施例1中方案(二)之4描述的方法,按常规方法收取斑马鱼受精卵。将上述sgRNA1和sgRNA3 (终浓度为50ng/μl)和Cas9蛋白(终浓度为200ng/μl)混合后,显微注入斑马鱼受精卵(注射量为1nl 每胚胎),制备ucp1基因敲除突变体之初建者(Founder)。
(二)F1突变体的筛选
1、F1代个体模板基因组DNA制备
1.1F1代斑马鱼的繁育与饲养
将注射了Cas9/sgRNA的F0胚胎饲养至性成熟,然后令其自由交配,获得F1胚胎。将F1胚胎按常规饲养至性成熟,进行基因型鉴定,筛选基因编辑突变体。
1.2组织无创取材
取3~4月龄的F1成鱼,剪取部分尾鳍组织,按顺序分别放入200μl PCR管中,然后置于冰上存放。
1.3基因组模板DNA制备
向含有尾鳍组织的200μl PCR管中加入南京尧顺禹生产的YSY buffer 10μl。快速离心后,将PCR管放入PCR仪中,进行如下反应:65℃30min,95℃5min,16℃1min,4℃。
2、目标基因组DNA的扩增
2.1含sgRNA识别位点的基因组序列
绿色高亮字体标识用于PCR扩增的引物序列,黄色高亮标识sgRNA识别位点序列。
2.2基因组片段扩增引物设计
F-ucp1-1:CAGTGCACACACATTATGTCAA
R-ucp1-1:GCATATTTCAGCATCCATTGC(RC:GCAATGGATGCTGAAATATGC)
2.3基因组DNA片段PCR扩增
2.3.1反应的组成
2×Mastermix(Vazyme)10μl、7μl的超纯水、1μl的正反向(F-phf8-1和R1R-phf8-1)引物(5μM) 和1μl的由1.3.2步骤获得的细胞基因组DNA模板。
2.3.2PCR反应条件
95℃3min,35×(95℃30s,56℃30s,72℃50s),72℃10min,4℃。
3、携带ucp1突变等位基因的F1突变体的筛选鉴定
将ucp1突变体的PCR产物直接送测序,通过峰图读取确认其突变体携带的突变等位基因的基因型。
3.1突变体3基因型的确认
3.1.1突变体3基因型及预测的突变等位基因编码的截短蛋白序列
3.1.2测序峰图(部分)
突变体3的目标基因组片段PCR扩增产物直接测序结果图(部分)见图3
3.1.3预测的突变基因编码的截短蛋白结构示意图
见图4。
3.2突变体15基因型的确认
3.2.1突变体15基因型及预测的突变等位基因编码的截短蛋白序列
3.2.2测序峰图(部分)
突变体15的目标基因组片段PCR扩增产物直接测序结果图(部分)见图5。
3.2.3预测的突变基因编码的截短蛋白结构示意图
突变体15携带的移码突变等位基因预测编码的截短蛋白结构示意图见图6。
4、结论:共筛选到2尾携带ucp1移码突变的F1突变斑马鱼。
实施例3斑马鱼ucp1功能缺失降低脂肪的累积
1、胚胎准备
携带ucp1突变的F1代杂合子斑马鱼养殖在南京尧顺禹生物科技有限公司斑马鱼独立养殖单元中,待其性成熟时,令F1代个体自由交配,按常规收集受精卵,所有胚胎及幼鱼养殖在室温28.5℃,待胚胎发育至4天时用于实验。
2、油红O的配制
购于Sigma公司,母液配置为0.5%(w/v),取0.5g油红O溶于100ml异丙醇中。
3、胚胎固定
取2g多聚甲醛在65℃水浴锅中溶于PBS中(76g NaCl,9.9g Na2HPO4,3.6gNaH2PO4,溶于10L水中, pH调至7.0),配置为4%PFA,用于固定4dpf胚胎。
4、油红O染色
1)取4天斑马鱼幼鱼,4%多聚甲醛4℃固定12小时
2)PBST洗2次
3)0.5%油红O室温染色4-6小时
4)PBST洗3次,60%异丙醇洗2次,每次5分钟
5)PBST洗一次,解剖镜下观测,数码照相机拍照记录。
5、基因型鉴定及结果分析
对经油红O染色的ucp1斑马鱼突变体,提取基因组,按实施例2所列写的方案对每个胚胎逐一进行 基因型鉴定。结果发现ucp1纯合突变的胚胎脂肪的积累明显减少(图7)。
Claims (10)
1.基于UCP1基因的人类肥胖症斑马鱼的建立与应用,其特征在首先提供了两个可有效引导Cas9识别斑马鱼ucp1基因的活性sgRNA,利用活性sgRNA制作了ucp1基因敲除的斑马鱼突变体,提供了作为人类肥胖症的斑马鱼模型,因而确立了斑马鱼ucp1基因可作为标识基因应用于筛选与建立治疗人类肥胖症的新药物与新方法。
2.如权利要求1所述的特征,可有效引导Cas9识别斑马鱼ucp1基因的活性sgRNA分别为sgRNA1和sgRNA3。
3.如权利1所述的特征,斑马鱼的突变体分别为携带了***5bp和***7bp的ucp1无效等位基因的杂合子,性成熟的杂合子自交产生的纯合子作为人类肥胖症的斑马鱼模型。
4.如权利3所述的斑马鱼模型,其斑马鱼仔鱼的年龄为受精后3天、4天、5天、6天和7天。
5.如权利3所述的斑马鱼模型,应用于筛选与建立治疗人类肥胖症的新药物与新方法。
6.如权利1所述的特征,ucp1基因作为人类肥胖症的标识基因,其纯合突变导致斑马鱼仔鱼脂肪堆积受到抑制。
7.如权利6所述的特征,斑马鱼ucp1基因表达水平的降低指示治疗人类肥胖症的新药物与新方法的筛选与建立。
8.如权利6所述的特征,斑马鱼ucp1基因可以进行各种基因修饰,包括但不仅限于在ucp1位点敲入荧光报告基因,以指示ucp1基因表达的减少,用于筛选与建立治疗人类肥胖症的新药物与新方法。
9.如权利6所述的特征,斑马鱼ucp1基因的调控序列可用于驱动包括但不限于荧光报告基因,以制备转基因斑马鱼,用于筛选与建立治疗人类肥胖症的新药物与新方法。
10.如权利要求1所述的特征,斑马鱼的ucp1基因可以是其它鱼类模式动物的ucp1基因作为标识基因,用于筛选与建立治疗人类肥胖症的新药物与新方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710545563.2A CN109207523A (zh) | 2017-06-29 | 2017-06-29 | 基于ucp1基因的人类肥胖症斑马鱼模型的建立与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710545563.2A CN109207523A (zh) | 2017-06-29 | 2017-06-29 | 基于ucp1基因的人类肥胖症斑马鱼模型的建立与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109207523A true CN109207523A (zh) | 2019-01-15 |
Family
ID=64993471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710545563.2A Pending CN109207523A (zh) | 2017-06-29 | 2017-06-29 | 基于ucp1基因的人类肥胖症斑马鱼模型的建立与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109207523A (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003061681A2 (en) * | 2002-01-25 | 2003-07-31 | DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung | Proteins involved in the regulation of energy homeostasis and organelle metabolism |
US20120210449A1 (en) * | 2011-02-14 | 2012-08-16 | National Tsing Hua University | Novel transparent zebrafish and preparation method thereof |
US20130074199A1 (en) * | 2011-09-13 | 2013-03-21 | Dana-Farber Cancer Institute, Inc. | Compositions and Methods for Brown Fat Induction and Activity Using FNDC5 |
US20140041063A1 (en) * | 2011-03-23 | 2014-02-06 | Transposagen Biopharmaceuticals, Inc. | Genetically Modified Rat Models for Obesity and Diabetes |
CN104195177A (zh) * | 2014-08-05 | 2014-12-10 | 南京大学 | 一种显著提高鱼类基因组编辑效率的方法 |
CN104928321A (zh) * | 2015-02-12 | 2015-09-23 | 中国科学院西北高原生物研究所 | 一种由Crispr/Cas9诱导的鳞片缺失斑马鱼模式及建立方法 |
CN105594664A (zh) * | 2016-02-16 | 2016-05-25 | 湖南师范大学 | 一种stat1a基因缺失型斑马鱼 |
CN106282241A (zh) * | 2016-08-05 | 2017-01-04 | 无锡市第二人民医院 | 通过CRISPR/Cas9得到敲除bmp2a基因的斑马鱼的方法 |
-
2017
- 2017-06-29 CN CN201710545563.2A patent/CN109207523A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003061681A2 (en) * | 2002-01-25 | 2003-07-31 | DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung | Proteins involved in the regulation of energy homeostasis and organelle metabolism |
US20120210449A1 (en) * | 2011-02-14 | 2012-08-16 | National Tsing Hua University | Novel transparent zebrafish and preparation method thereof |
US20140041063A1 (en) * | 2011-03-23 | 2014-02-06 | Transposagen Biopharmaceuticals, Inc. | Genetically Modified Rat Models for Obesity and Diabetes |
US20130074199A1 (en) * | 2011-09-13 | 2013-03-21 | Dana-Farber Cancer Institute, Inc. | Compositions and Methods for Brown Fat Induction and Activity Using FNDC5 |
CN104195177A (zh) * | 2014-08-05 | 2014-12-10 | 南京大学 | 一种显著提高鱼类基因组编辑效率的方法 |
CN104928321A (zh) * | 2015-02-12 | 2015-09-23 | 中国科学院西北高原生物研究所 | 一种由Crispr/Cas9诱导的鳞片缺失斑马鱼模式及建立方法 |
CN105594664A (zh) * | 2016-02-16 | 2016-05-25 | 湖南师范大学 | 一种stat1a基因缺失型斑马鱼 |
CN106282241A (zh) * | 2016-08-05 | 2017-01-04 | 无锡市第二人民医院 | 通过CRISPR/Cas9得到敲除bmp2a基因的斑马鱼的方法 |
Non-Patent Citations (6)
Title |
---|
ASHA SETH等: "The emerging use of zebrafish to model metabolic disease", 《DISEASE MODELS & MECHANISMS》 * |
刘凯: "超低温冷冻保存对鱼类***线粒体功能、氧化损伤机制与UCP2表达的影响", 《万方学位论文》 * |
梁旭方等: "鱼类解偶联蛋白(UCP)基因研究新进展", 《水产学报》 * |
王彦芹等: "《现代分子生物学实验指导》", 31 March 2017, 西安交通大学出版社 * |
董润安等: "《光敏化氧化反应的化学生物学》", 30 June 2016, 北京理工大学出版社 * |
陈坤: "文昌鱼解偶联蛋白的分子克隆以及利用点突变的方法研究UCP1解偶联功能与结构之间的关系", 《中国博士学位论文全文数据库(基础科学辑)》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cui et al. | Genome editing reveals dmrt1 as an essential male sex-determining gene in Chinese tongue sole (Cynoglossus semilaevis) | |
CN104928321B (zh) | 一种由Crispr/Cas9诱导的鳞片缺失斑马鱼模式及建立方法 | |
WO2018177351A1 (zh) | 基于CRISPR/Cas9技术的制备无嵌合基因敲除动物的方法 | |
CN109207524A (zh) | 基于fto基因的人类肥胖症斑马鱼模型的建立与应用 | |
Qu et al. | Seadragon genome analysis provides insights into its phenotype and sex determination locus | |
Zhou et al. | Programmable base editing of the sheep genome revealed no genome-wide off-target mutations | |
CN109706184B (zh) | 自闭症模型犬的建立方法 | |
CN106282231B (zh) | 粘多糖贮积症ii型动物模型的构建方法及应用 | |
CN108531487A (zh) | 人源化sirpa基因改造动物模型的制备方法及应用 | |
Horie et al. | Investigation of Oxtr-expressing neurons projecting to nucleus accumbens using Oxtr-ires-Cre knock-in prairie voles (Microtus ochrogaster) | |
Ruiz-Estevez et al. | Liver development is restored by blastocyst complementation of HHEX knockout in mice and pigs | |
Dai et al. | The overexpression of tβ4 in the hair follicle tissue of Alpas cashmere goats increases cashmere yield and promotes hair follicle development | |
CN109295104A (zh) | 一种Slco1b2基因敲除大鼠的构建方法及应用 | |
Liu et al. | Fgf21 knockout mice generated using CRISPR/Cas9 reveal genetic alterations that may affect hair growth | |
CN105002215A (zh) | 一种含有可调控表达的cre重组酶基因和报告基因LacZ的表达载体及其构建方法和应用 | |
Cheung et al. | Double maternal-effect: duplicated nucleoplasmin 2 genes, npm2a and npm2b, with essential but distinct functions are shared by fish and tetrapods | |
CN106521638A (zh) | 一种基因突变大鼠资源库及其制备方法 | |
CN101948860A (zh) | 受四环素诱导表达***调控uPA表达的载体及其应用 | |
CN114480497B (zh) | 一种ep400基因敲除斑马鱼心力衰竭模型的构建及其应用的方法 | |
WO2013088110A1 (en) | Annexin-a1 transgenic animals | |
CN109207523A (zh) | 基于ucp1基因的人类肥胖症斑马鱼模型的建立与应用 | |
CN112626122B (zh) | hKDR人源化小鼠模型及其建立方法和应用 | |
Chen et al. | Genome-Wide Association study reveals SNPs and candidate genes related to growth and body shape in Bighead carp (Hypophthalmichthys nobilis) | |
CN109694885B (zh) | 基于CRISPR/Cas9技术制备PI3Kγ全身敲除模式小鼠方法及其应用和试剂盒 | |
CN114763557A (zh) | Ddx5在抗病毒和调节免疫反应中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190115 |
|
WD01 | Invention patent application deemed withdrawn after publication |